SEARCH

SEARCH BY CITATION

References

  • 1
    Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med 2005; 118: 1413.
  • 2
    Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003; 362: 208994.
  • 3
    Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 2004; 350: 111829.
  • 4
    Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006; 36: 10013.
  • 5
    Jacobson IM. Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol 2006; 101 (Suppl. 1): S138.
  • 6
    Lau GK. Hepatitis B infection in China. Clin Liver Dis 2001; 5: 36179.
  • 7
    Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepatol 2005; 12: 33345.
  • 8
    Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132: 72331.
  • 9
    Barbaro G, Zechini F, Pellicelli AM, et al. Lamivudine Italian study group investigators. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35: 40611.
  • 10
    Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41: 135764.
  • 11
    Jang MK, Chung YH, Choi MH, et al. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 19: 13638.
  • 12
    Perrillo RP. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 2005; 25 (Suppl. 1): 208.
  • 13
    Akarca US, Ersoz G, Gunsar F, et al. Interferon–lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 2004; 9: 32534.
  • 14
    Schiff ER, Dienstag JL, Karayalcin S, et al. International lamivudine investigator group. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38: 81826.
  • 15
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 16
    Yalcin K, Degertekin H, Yildiz F, et al. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003; 36: 151622.
  • 17
    Cindoruk M, Karakan T. Efficacy of interferon alfa and lamivudine combination therapy versus interferon alfa monotherapy in Turkish patients with chronic hepatitis B: a double-blind, randomized, comparative study. Curr Ther Res 2002; 63: 16775.
  • 18
    Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 19
    Ayaz C, Celen MK, Colak H, Hosoglu S, Geyik MF. Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J Gastroenterol 2006; 25: 713.
  • 20
    Song JW, Zhang G, Lin JG, Tang WX, Lin JS. Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication. Zhonghua Gan Zang Bing Za Zhi 2004; 12: 5936 (in Chinese).
  • 21
    Deng QW, Wu CH, Yang J, et al. Clinical observation on the therapeutic efficacy of interferon-α combined with lamivudine in the treatment of patients with chronic hepatitis B. J Clin Res 2003; 20: 5035.
  • 22
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a HBeAg-positive chronic hepatitis B study group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 23
    Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 1239.
  • 24
    Flink HJ, Hansen BE, Heathcote EJ, et al. HBV 99-01 study group. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 2006; 101: 25239.
    Direct Link:
  • 25
    Jaboli MF, Fabbri C, Liva S, et al. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial. World J Gastroenterol 2003; 9: 14915.
  • 26
    Van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. HBV 99-01 study group. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006; 26: 399405.
  • 27
    Hui CK, Lau GK. Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B. Expert Rev Anti Infect Ther 2005; 3: 495504.
  • 28
    Craxi A, Cooksley WG. Pegylated interferons for chronic hepatitis B. Antiviral Res 2003; 60: 879.
  • 29
    Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 1200.
  • 30
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 31
    Karabay O, Tamer A, Tahtaci M, et al. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005; 38: 2626.
  • 32
    Liu CJ, Lai MY, Chao YC, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43: 7429.
  • 33
    Hadziyannis S, Alexopoulou A, Papakonstantinou A, et al. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study. J Viral Hepatol 2000; 7: 23540.
  • 34
    Rigopoulou EI, Suri D, Chokshi S, et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005; 42: 102836.
  • 35
    Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996; 15: 22331.
  • 36
    Lim SG, Krastev Z, Ng TM, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 2006; 50: 16428.
  • 37
    Lai CL, Leung N, Teo EK, et al. Telbivudine phase II investigator group. 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 52836.
  • 38
    Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 39
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 40
    Lau GK, Tsiang M, Hou J, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32: 394.